✦ LIBER ✦

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry

✍ Scribed by Peter de Bruijn; Inge M. Ghobadi Moghaddam-Helmantel; Maja J.A. de Jonge; Thorsten Meyer; Mei-Ho Lam; Jaap Verweij; Erik A.C. Wiemer; Walter J. Loos

Book ID: 108189681
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 318 KB
Volume: 50
Category: Article
ISSN: 0731-7085
DOI: 10.1016/j.jpba.2009.06.048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bioanalytical method for the quantificat

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

✍ Peter de Bruijn; Stefan Sleijfer; Mei-Ho Lam; Ron H.J. Mathijssen; Erik A.C. Wie 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 607 KB

Highly sensitive method for the determin

Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography–electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study

✍ Sandip Dhondiram Gurav; Ravindranath Reddy Gilibili; Sherine Jeniffer; Sanjeev G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 590 KB

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti